Effect of Simvastatin Nanohybrid drug on Liver Tissue and Some of Oxidation Indicators in White Male Rats Induced with Hyperlipidemia

Article Sidebar

Published: Dec 1, 2020
Keywords:
Simvastatin Nanoparticles Antioxidants Rats
Dimensions Badge

Main Article Content

Aseel Najah Sabour
Department of Biology, College of Education, University of Al-Qadisiyah, Iraq
Zainab Zaidan Mtashar
Department of Biology, College of Education, University of Al-Qadisiyah, Iraq

Abstract

Objectives: This study was designed to determine the effect of the nanohybrid hypolipidemic of simvastatin drug on Liver tissue and some of oxidation indicators(GSH and MDA) in white male rats induced hyperlipidemia. Methods: The nanohybrid compound of the drug was initially prepared and diagnosed as the drug was loaded onto zinc oxide layers. Results: The results of the test showed the infrared spectrum FT-IR obtained many of the distinctive movements of the bonds and group. XRD also showed a new diffraction in the spectrum of the nanohybrid drug compared to the zinc oxide carrier spectrum, indicating that the drug under study was a nanohybrid drug. The results of the examination of the atomic force microscope revealed that the average diameter of the nanoparticles of the hybrid drug Sim-Zno was 92.28 nm. To test the effectiveness of this compound compared to free simvastatin, the current study included two experiments, the first experiment used 50 males of adult white rats divided into two groups, the first group (control) fed normal diet and distilled water, the second group was induced hyperlipidemia by feeding on (cholesterol 2%, bile acid salt 3% and lard fat 8%) for two months. It was ascertained of hyperlipidemia by measuring lipid profile, the results showed increased high blood lipid levels compared with control group. The second experiment divided the remaining animals from the second group in addition to the control group to five groups, control group considered as negative control, T1 group as positive control, T2 , T3 and T4 groups were administered with the free 40 mg/kg simvastatin drug , nanohybrid compound of the drug at a dose 40mg/kg and Zinc oxide at a dose of 30 mg/kg respectively and concurrently fed with high-fat diet for 30 days. The results showed a significant increase in the level of MDA and a significant decrease in GSH level in the T1 group (positive control) compared with negative control with many histopatholgical changes in the hepatocytes resulted from fat accumulation in it. Conclusion: Nanohybrid compound of the simvastatin have a role in improvement oxidation indicators levels and histopatholgical changes of liver by increasing the bioavailability of drug and increasing its absorption.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sabour, A. N. ., & Mtashar, Z. Z. . (2020). Effect of Simvastatin Nanohybrid drug on Liver Tissue and Some of Oxidation Indicators in White Male Rats Induced with Hyperlipidemia. Scientific Journal of Medical Research, 4(16), 152–153. Retrieved from https://sjomr.org.in/index.php/SJOMR/article/view/138
Issue
Vol. 4 No. 16 (2020): SCIENTIFIC JOURNAL OF MEDICAL RESEARCH
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

Knight J.A. "Diseases and disorders associated with excess body weight". Annals of Clinical &Laboratory Sciences. 2011; 41(2): 107-121.

Boden G. "Obesity, insulin resistance and free fatty acids". Current opinion in endocrinology, diabetes, and obesity. 2011; 18(2): 139-43. DOI: 10.1097/MED.0b013e3283444b09.

Zalesin K.C., Franklin B.A., Miller W.M., Peterson E.D. and McCullough P.A. "Impact of obesity on cardiovascular disease". Endocrinology and metabolism clinics of North America. 2011; 37(3): 663-684. DOI: 10.1016/j.mcna.2011.06.005.

Franssen R., Monajemi H., Stroes E.S. and Kastelen J.J. "Obesity and dyslipidemia ". Med.Clin.North. 2011; 95(5): 893-902. DOI:https://doi.org/10.1016/j.mcna.2011.06.003.

Wang H. and Peng D.Q. "New insights into the mechanism of low high-density lipoprotein cholesterol in obesity". Lipids in health and disease. 2011; 10(1): 176. DOI: 10.1186/1476-511X-10-176.

Adam E., Sower Q.R. and Brman M.D. "Atherosclerosis and its causes and risks factors".American Medical Encyclop. 2002.

Zureik M., Galan P., Bertrais S., Mennen L., Czernichow S., Blacher J., ... and Hercberg S. "Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries". Arteriosclerosis, thrombosis, and vascular. Biology. 2004; 24(8): 1485-1491. DOI: doi.org/10.1161/01.ATV.0000136648.62973.c8.

Hippisley-Cox J. and Coupland C. "Unintended effects of statins in men and women in England and Wales: population based cohort studyusing the Q Research database". BMJ. 2010; 340: c2197.

Katzung B.G. "Special aspects of geriatric pharmacology. Basic & Clinical Pharmacology". 9th ed. New York: Lange Medical Books/McGraw-Hill. 2004; 1007-1014.

Yanuck D., Mihos C.G. and Santana O. "Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review". International Journal of Neuroscience. 2012; 122(11): 619-629. DOI: 10.3109/00207454.2012.704455.

Bellosta S., Bernini F., Paoletti R. and Corsini A. "Non-lipid-related effects of statins". Annals of medicine. 2000; 32(3): 164-176. DOI: 10.3109/07853890008998823.

Black D.M. "A general assessment of the safety of HMG CoA reductase inhibitors (statins)". Current atherosclerosis reports. 2002; 4(1): 34-41. DOI: 10.1007/s11883-002-0060-0.

Obeidi A.M.A.F. "Nanotechnology and its advanced applications in medicine, genetic engineering and molecular biology". First Edition. Book and documents in Baghdad. 2012.

Kolekar T.V., Yadav H.M., Bandgar S.S. and Deshmukh P.Y. "Synthesis By Sol-gel Method And Characterization Of Zno Nanoparticles".Indian Streams Research Journal. 2011; 1(1):14.

Pengzhan Y., Quanbin Z., Ning L., Zuhong X., Yanmei W. and Zhi'en L. "Polysaccharides from Ulva pertusa (Chlorophyta) and preliminary studies on their antihyperlipidemia activity". Journal of applied phycology. 2003; 15(1): 21-27. DOI: https://doi.org/10.1023/A:1022997622334.

Hassan H.A.H.A. "Effects of Hypolip(Simvastatin) on lipid profile and renal functions in an induced hypercholestrolemic rats".

MSc. Thesis. University of Khartoum faculty of veterinary medicine. 2009.

Sedlak J. and Lindsay R.H. "Analytical Biochemistry". 1968; p. 192. Cited by Al-Zamyle O.M., Al-Naner M.S. and Al-Muslish R.K. "Detection the levele of peroxynitrite and related with antioxidant state in the serum of patients with acute myocardial infection". Nat. J. Chem. 2001; 4: 625-637.

Guidet B. and Shah S.V. "The level of Malondialdehyde after activation with H2O2 and CuSO4 and inhibition by deferoxamine and Molsidomine in the serum of patient with acute Myocardial infraction". Am.J.Physiolo. 1989; 257(26):F440. cited by Muslih R.K., Al-nimer M.S. and Al-Zamely O.Y. Nati. J. Chem. 2002; 5: 139-148.

Humason G. "Humason animal tissue techniques".5th ed. London. 1997.

Allen J. and Bradley R.D. "Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers". Journal of alternative and complementary medicine. 2012; 17(9): 827-33. DOI: 10.1089/acm.2010.0716.

Ali S., Fark A. and Haider H. "Biochemical study on the association of selenium with hormones of thyroid gland in patients with disorder". Kerbala Journal of Pharmaceutical Science. 2012; (3):45-241.

Eric M. and Osansky D.C. "Natural treatment solution for hyperthyroidism and graves' disease". Amazon Kindle. 2013; (27):10-13.

Suleyman D., Mustafa Y., Mchmet K., Natan A., Divler A. and Ahmet A. "Role of free radicals in peptic ulcer andgastriis". Turk. J. Gastroenterol. 2003; 14(1):39-43.

Murry R.K., Granner D.K., Mayes D.A. and Rod well V.W. "Harpers Illustrated Biochemistry". 26th ed. Appeton and lang. USA. 2003; Pp:180:223- 352.

Chen J.J., and Li X.R. "Hypolipidemic effect of flavonoids from mulberry leaves in triton WR-1339 induced hyperlipidemic mice". Asia Pacific journal of clinical nutrition. 2007; 16(S1): 290-294.

Prasad K. "Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed". Circulation. 1999; 99(10): 1355-1362. DOI: 10.1161/01.cir.99.10.1355.

Martinet W., Knaapen M.W., De Meyer G.R., Herman A.G. and Kockx M.M. "Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering". Circulation Research. 2001; 88(7): 733-739. DOI: 10.1161/hh0701.088684.

Lazarow P.B. and De Duve C. "A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug". Proceedings of the National Academy of Sciences.1976; 73(6): 2043-2046. DOI:10.1073/pnas.73.6.2043.

Basha B.J. and Sovers J.R. "Atherosclerosis: an update". Am. Heart. J. 1996; 131: 1192-1202.

Lovric J., Mesic M., Macan M., Koprivanac M., Kelava M. and Bradamante V. "Measurement of malondialdehyde (MDA) level in rat plasma after simvastatin treatmement using two different analytical methods". Periodicum biologorum. 2008; 110(1): 63-68.

Sci. J. Med. Res. Vol. 4, Issue 16, pp 125- 133 Autumn 2020 132

.

Mohamadin A.M., Elberry A.A., Abdel Gawad H.S., Morsy G.M. and Al-Abbasi F.A. "Protective effects of simvastatin, a lipid lowering agent, against oxidative damage in experimental diabeticrats". Journal of lipids. 2011; 2011: 167958. DOI: 10.1155/2011/167958.

Mahmoud H.M., Zaki H.F., El Sherbiny G.A. and El-Latif H.A.A. "Effects of Simvastatin and Vitamin E on Diet-induced Hypercholesterolemia in Rats". British Journal of Pharmacology and Toxicology. 2014; 5(1): 16-25.

Tandon V., Bano G., Khajuria V., Parihar A. and Gupta S. "Pleiotropic effects of statins". Indian journal of pharmacology. 2005; 37(2): 77.

Deskur-Smielecka E., Wykretowicz A., Kempa M., Furmaniuk J. and Wysocki H. "The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia". Coronary artery disease. 2001; 12(2): 143-148. DOI: 10.1097/00019501-200103000-00008.

Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L. and Hazen S.L. "Statins promote potent systemic antioxidant effects through specific inflammatory pathways". Circulation. 2003; 108(4): 426-431. DOI: https://doi.org/10.1161/01.CIR.0000080895.05158.8B

Maheshwari R.A., Sailor G.U., Patel L. and Balaraman R. "Amelioration of cisplatin-induced nephrotoxicity by statins". Indian journal of pharmacology. 2013; 45(4): 354-358. DOI: 10.4103/0253-7613.115016.

Harisa G.I., Alomrani A.H. and Badran M.M. "Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats". European Journal of Pharmaceutical Sciences. 2017; 96: 62-71. DOI: 10.1016/j.ejps.2016.09.004.

Kulikowska-Karpinska E. and Moniuszko-Jakoniuk J. "Lead and zinc influence on antioxidant enzyme activity and malondialdehyde concentrations". Polish Journal of Environmental Studies. 2001; 10(3): 161-16.